CSNK1D and plasma cell myeloma: Previous studies demonstrated the oncogenic role of CSNK1D in various cancers, including breast carcinoma [6, 7], hepatocellular carcinoma [8, 9], prostate cancer [10], glioblastoma [11], multiple myeloma [12], and bladder cancer [13].